Biosimilars Congregation 2012
"Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars" February 24th 2012, Hilton London Euston Hotel, London UK.
- (1888PressRelease) December 21, 2011 - Key Themes Discussed at this Summit:
• Reviewing some of the challenges in clinical study design for biosimilar development arising from endpoint variability, changes in clinical practice, and evolution in understanding of the biology of the disease
• How should the pharma and generics industries approach the rapidly emerging and developing biosimilar market? The future of next generation Biosimilars
• How are policy makers shaping the contours of this new generic frontier, and what implications they have for current biologic drug development and patent protection?
• Identifying issues and solutions surrounding biosimiliars and clinical trials.
• Next generation monoclonal antibody development and clinical challenges with biosimilar drug development
• Overcoming pricing and reimbursement challenges to maximise the ROI
• Determining the right investments & potential returns from Biosimilars
• Commercial challenges and opportunities - strategies to develop Biosimilars
• Biosimilars Vs Bio-betters - positioning for a new market with lucrative prospects
• Learn to implement best practices through recent successful strategies and business models - real time case studies
• Analyze the FDA's current view of biosimilars
• The developing regulatory framework in advanced and developing markets
• EMA Regulatory Opinions on Treatment of mAbs
• Critical issues in demonstrating biosimilarity and maintaining diligent quality control
• Be part of a major networking opportunity
Who Should Attend:
CSOs, CMOs, Vice Presidents, Presidents, Heads, Directors, Team Leaders, and Senior Scientists from the following roles:
• Analytics
• Business Development
• Business Strategy
• Corporate Development Strategy
• Commercial Affairs
• Intellectual Property
• Marketing & Sales
• Medical Affairs
• NewProduct Development
• Legal Affairs
• CMC
• Preclinical and Clinical Development
• Product Development
• Regulatory Affairs
• Pricing and Reimbursement
• Research and Development
• Biologic Production
• Quality Assurance
• Scientific Affairs
• Strategic Planning
• Strategic Sourcing
Key Speakers Include:
• Claudio Carini, Translational Medicine, Pfizer
• Deven Parmar, Vice President - Global Clinical Research, Wockhardt (India)
• Paul Greenland, Biosimilars and Proprietary Marketing Director - EMEA, Hospira, UK
• Keith Powell, Chairman, Domainex (Former CEO, Polytherics)
• Cecil Nick, Vice President - Biotechnology, Parexel
• Richard Dennett, Director, Voisin Consulting Life Sciences
• Lincoln Tsang, Partner, Arnold & Porter LLP
• Kristie C. Kuhl, Senior Vice President, Makovsky + Company (USA)
• Violeta Stanimirovic, Expert of medicines and medical devices agency, Serbia-Alims & expert of Montenegrian National Drug Agency - CALIMS
• Francis P. Crawley, Executive Director, Good Clinical Practice Alliance - Europe (GCPA)
• Anthony Grosso, Associate Professor in Clinical Pharmacy Practice (Honorary), UCL Hospitals NHS Trust, University of London
• Jan Petracek, MD MSc DIC CEO, Pharminvent
• Anna Harrington Morozova, Scientific & Regulatory Director, REGEM Consulting
• Steinar Madsen, Medical Director, Norwegian Medicines Agency
• Duncan Emerton, Prinicpal Consultant, Datamonitor
plus many more.........
Why Should You Attend:
Biosimilars Congregation 2012 - "Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars"
Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.
Ordering Delegate Place -
Register now as delegate, sponsor and exhibitor
Early Bird Discounted Price - Conference Delegate Pass (£ 400 + VAT per delegate) - Book and Pay before 20th December 2011 to avail the early bird discounted price. You can simply email or call and book your conference delegate seats on TEL (Uk): + 44 20 3302 4659. TEL (India): + 91 44 64536444.
Email - tania @ virtue insight . com
Standard Price after 20th December 2011 - Conference Delegate Pass (£ 500 + VAT per delegate) - You can simply email or call and book your conference delegate seats on TEL (Uk): + 44 20 3302 4659. TEL (India): + 91 44 64536444..
Email - tania @ virtue insight . com
Group Discounts - 2 or 3 Delegates - £ 350 + VAT per delegate
Group Discounts - 4 and above Delegates - £ 300 + VAT per delegate
Conference Sponsor & Exhibition Stall - Should you wish to Sponsor, or purchase a Exhibiton Stall (Booth) or a paid Speaker Slot, you can simply email your interest and queries to - TEL (Uk): + 44 20 3302 4659. TEL (India): + 91 44 64536444.
Email - tania @ virtue insight . Com
For more info on the event and for event brochure kindly visit -
h t t p : / / w w w . virtue insight . com / pharma / Biosimilars - Congregation - 2012 /
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam